Western blot analysis: treatment effect within gendera and genderb differences(percentage density relative to total tau values)
| Insoluble tau: PHF1 | Soluble tau: PHF1 | Insoluble tau: MC1 | Soluble tau: MC1 | |||||
|---|---|---|---|---|---|---|---|---|
| M | F | M | F | M | F | M | F | |
| 2–5 months | ||||||||
| Tg control | 184 ± 35 | 96 ± 33 | 122 ± 15 | 169 ± 57 | 12 ± 3 | 17 ± 3 | 7 ± 1 | 3 ± 1+ |
| Tg Phos-tau | 116 ± 12 | 95 ± 13 | 282 ± 46** | 218 ± 52 | 18 ± 6 | 27 ± 8 | 20 ± 9 | 7 ± 2* |
| 2–8 months | ||||||||
| Tg control | 39 ± 11 | 96 ± 24 | 111 ± 15 | 55 ± 6++ | 11 ± 3 | 15 ± 6 | 54 ± 14 | 12 ± 4++ |
| Tg Phos-tau | 38 ± 13 | 68 ± 14 | 77 ± 14 | 62 ± 5 | 11 ± 2 | 32 ± 21 | 56 ± 13 | 9 ± 3++ |
↵aTreatment effect within gender: In the 2−5 month study, significantly more effect of the immunization on pathological tau was observed between males in levels of soluble PHF1 tau and in females in levels of soluble MC1. *p ≤ 0.05, **p ≤ 0.01, significantly different from control mice within the same gender.
↵bGender differences: Significant gender differences were observed between some of the groups, but these differences were not as prevalent as in the immunohistochemical analysis. In the 2−5 month study, male (n = 8) and female (n = 6) controls differed in soluble tau levels (MC1) but not Phos-tau-immunized males (n = 5) and females (n = 7). A similar pattern was observed in the immunohistochemical analysis with differences only observed in control groups. In the 2−8 month study (six males and six females per group), this difference was not as group specific with differences observed in soluble tau (MC1, PHF1) within controls. In the Phos-tau-immunized mice, gender differences were detected in soluble tau (MC1). +p ≤ 0.05, ++p ≤ 0.01, significantly different from males within the same treatment group.